Zimbabwe has turned down a substantial American health deal worth 367 million US dollars (272 million pounds) spanning five years due to the United States' insistence on confidential data.
The decision was revealed following a government memo dated December was leaked, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesman later explained that the United States was seeking genetic material for scientific study and profit but was not willing to guarantee the benefits from future treatments.
"We are forced to start the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for further dialogue to secure a deal acceptable to all parties so the country's vital HIV programme can be sustained.
Wider Context
This development follows a comparable case in Kenya, where a high court suspended a similar health funding agreement following concerns were raised about the safety of citizens' health data.
Since returning to office last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump argued its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
According to statements, 16 African countries have to date signed these new agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy via American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that could be developed from that provided information," he stated.
"Put simply, our nation would supply the raw materials for medical research without any assurance that the end products would be accessible to our citizens should a future disease outbreak arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending structures already set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This system is designed to ensure that when a country contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how future co-operation might be arranged in a manner that respects the independence and interests of both nations."
Medical Community Response
A leading public health body said it understood the official position, but suggested that talks must proceed considering a large portion of the country's Aids initiatives were funded by international support.
"If specific concerns exist, such as those relating to information security or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," it added.
The situation underscores the complex tensions between accepting crucial foreign assistance and safeguarding local interests in an increasingly data-driven world.